203 related articles for article (PubMed ID: 8913935)
21. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
Ulfgren AK; Andersson U; Engström M; Klareskog L; Maini RN; Taylor PC
Arthritis Rheum; 2000 Nov; 43(11):2391-6. PubMed ID: 11083259
[TBL] [Abstract][Full Text] [Related]
22. [Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives].
Meyer O
Bull Acad Natl Med; 2003; 187(5):935-54; discussion 954-5. PubMed ID: 14979058
[TBL] [Abstract][Full Text] [Related]
23. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression.
Netea MG; Radstake T; Joosten LA; van der Meer JW; Barrera P; Kullberg BJ
Arthritis Rheum; 2003 Jul; 48(7):1853-7. PubMed ID: 12847679
[TBL] [Abstract][Full Text] [Related]
24. Role of cytokines in rheumatoid arthritis.
Feldmann M; Brennan FM; Maini RN
Annu Rev Immunol; 1996; 14():397-440. PubMed ID: 8717520
[TBL] [Abstract][Full Text] [Related]
25. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes.
Meusch U; Rossol M; Baerwald C; Hauschildt S; Wagner U
Arthritis Rheum; 2009 Sep; 60(9):2612-21. PubMed ID: 19714631
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
di Comite G; Marinosci A; Di Matteo P; Manfredi A; Rovere-Querini P; Baldissera E; Aiello P; Corti A; Sabbadini MG
Ann N Y Acad Sci; 2006 Jun; 1069():428-37. PubMed ID: 16855170
[TBL] [Abstract][Full Text] [Related]
27. [New therapeutic methods against rheumatoid arthritisp6. Antibodies against TNFalpha significant for the progress].
Bondeson J
Lakartidningen; 1997 Jan; 94(1-2):42-5. PubMed ID: 9053603
[TBL] [Abstract][Full Text] [Related]
28. [Anti-TNF-alpha therapy as a new option in treatment of rheumatoid arthritis?].
Leeb BF; Sautner J
Wien Med Wochenschr; 1999; 149(19-20):554-7. PubMed ID: 10637966
[TBL] [Abstract][Full Text] [Related]
29. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
30. [Cytokines and their antagonists in the treatment of rheumatoid arthritis].
Klimiuk PA; Sierakowski S
Przegl Lek; 2002; 59(2):108-12. PubMed ID: 12152246
[TBL] [Abstract][Full Text] [Related]
31. [Cytokines in rheumatoid arthritis. I. Proinflammatory cytokines].
Klimiuk PA; Sierakowski S
Pol Merkur Lekarski; 2001 Dec; 11(66):510-3. PubMed ID: 11899850
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the inflammatory cytokine network among TNF alpha, IL-1 beta, IL-1 receptor antagonist, and IL-8 in LPS-induced rabbit arthritis.
Matsukawa A; Yoshimura T; Miyamoto K; Ohkawara S; Yoshinaga M
Lab Invest; 1997 May; 76(5):629-38. PubMed ID: 9166282
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?
Dayer JM
J Rheumatol Suppl; 2002 Sep; 65():10-5. PubMed ID: 12236616
[TBL] [Abstract][Full Text] [Related]
34. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.
Kim WU; Yoo WH; Park W; Kang YM; Kim SI; Park JH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY
J Rheumatol; 2000 Mar; 27(3):575-81. PubMed ID: 10743792
[TBL] [Abstract][Full Text] [Related]
35. The TNF-alpha transgenic mouse model of inflammatory arthritis.
Li P; Schwarz EM
Springer Semin Immunopathol; 2003 Aug; 25(1):19-33. PubMed ID: 12904889
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists.
Jazayeri JA; Carroll GJ; Vernallis AB
Int Immunopharmacol; 2010 Jan; 10(1):1-8. PubMed ID: 19804846
[TBL] [Abstract][Full Text] [Related]
37. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?
Feldmann M; Maini RN
J Immunol; 2010 Jul; 185(2):791-4. PubMed ID: 20601610
[TBL] [Abstract][Full Text] [Related]
38. What have we learnt from targeted anti-TNF therapy?
Feldmann M; Williams RO; Paleolog E
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i97-99. PubMed ID: 19995756
[TBL] [Abstract][Full Text] [Related]
39. Targeting TNF alpha for the therapy of rheumatoid arthritis.
Maini RN; Elliott M; Brennan FM; Williams RO; Feldmann M
Clin Exp Rheumatol; 1994; 12 Suppl 11():S63-6. PubMed ID: 7768056
[TBL] [Abstract][Full Text] [Related]
40. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.
Camussi G; Lupia E
Drugs; 1998 May; 55(5):613-20. PubMed ID: 9585859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
